Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2009; 30(03): 103-104
DOI: 10.4103/0971-5851.64255
CASE REPORT

Persistent hypokalemia in an acute lymphoblastic leukemia patient

Altaf Ali
Department of General Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India
,
Sheikh Ajaz Aziz
Department of General Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India
,
Afaq Khan
Department of General Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India
,
Sajad Gelani
Department of General Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Nephrotoxicity is an important adverse effect of Amphotericin B, and although risk factors for nephrotoxicity in adults have been investigated, studies examining nephrotoxicity in the pediatric population are scarce. We describe case of 10 year old boy (CALLA - VE B cell ALL) who received conventional Amphotericin-B, but he persisted with hypokalemia.

Keywords

Trans-tubular potassium gradient - venous blood gas - nephrotoxicity


Publication History

Article published online:
19 November 2021

© 2009. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 2004;26:421-6.
  • 2 White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, et al. Randomized, double-blind clinical trial of amphoterin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
  • 3 Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
  • 4 Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-8.
  • 5 Sawaya PB, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995;6:154-64.
  • 6 Tonomura Y, Yamamoto E, Kondo C, Itoh A, Tsuchiya N, Uehara T, et al. Amphotericin B-induced nephrotoxicity: characterization of blood and urinary biochemistry and renal morphology in mice. Hum Exp Toxicol 2009;28:293-300.